Can over-the-counter drugs reduce risk of developing genetic Parkinson’s?

News

Author: Pippa Prendergast-CoatesPublished: 6 August 2020

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Close up woman holding pill in hand with water. Female going to take tablet from headache, painkiller, medication drinking clear water from glass. Healthcare, medicine, treatment, therapy concept

A new study suggests that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen may lower the risk of Parkinson’s associated with mutations of the LRRK2 gene – a common genetic cause of the condition.

As part of the study, researchers analysed the data for 577 individuals with the LRRK2 gene mutation. They found that regular use of aspirin and ibuprofen – at least two pills per week for at least six months – was more prevalent in people who did not have Parkinson’s compared to those with the condition. Across the study, the use of NSAIDs corresponded with roughly a 66% decrease in the risk of Parkinson’s.

The researchers say that “the results of this study suggest that the regular use of NSAID medication may lower the risk for Parkinson’s among LRRK2 variant carriers … for both ibuprofen and aspirin” but more research will need to be conducted to find the optimal use.

For more information on the latest Parkinson’s research please visit the EPDA website.


Read more:

US hospital initiative improves on-time administration of Parkinson’s medication

Does deep brain stimulation for Parkinson’s increase the risk of dementia?

Go Back

Share this story

Comments


Related articles


Resources & Tools

6 free guides to help raise awareness of Parkinson’s

Start campaigning this Parkinson’s Awareness Month

READ MORE
Webinar pain and fatigue

PD in Practice

WEBINAR: Get expert advice on managing Parkinson’s pain and fatigue

Join this free MJ Fox Foundation live webinar

READ MORE
Faii-ong-gyroglove-lead

Advances

Tremor-reducing GyroGlove set to launch in 2017

Volunteer testers wanted as launch date nears

READ MORE